Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Major Shareholder Sells $152,994.96 in Stock

Share on StockTwits

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 13,212 shares of the company’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $11.58, for a total value of $152,994.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Monday, July 8th, Matt Davidson sold 12,529 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.27, for a total value of $141,201.83.
  • On Tuesday, July 2nd, Matt Davidson sold 33,521 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.63, for a total value of $389,849.23.
  • On Tuesday, June 25th, Matt Davidson sold 210 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $10.04, for a total value of $2,108.40.
  • On Thursday, June 13th, Matt Davidson sold 2,131 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $9.65, for a total value of $20,564.15.
  • On Tuesday, June 11th, Matt Davidson sold 4,345 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $8.49, for a total value of $36,889.05.
  • On Thursday, June 6th, Matt Davidson sold 5,507 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $7.27, for a total value of $40,035.89.
  • On Monday, June 3rd, Matt Davidson sold 4,110 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $7.36, for a total value of $30,249.60.
  • On Wednesday, May 29th, Matt Davidson sold 2,100 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $8.41, for a total value of $17,661.00.
  • On Thursday, May 23rd, Matt Davidson sold 2,422 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $8.80, for a total value of $21,313.60.
  • On Monday, May 20th, Matt Davidson sold 1,800 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $8.95, for a total value of $16,110.00.

Shares of NASDAQ VRCA opened at $11.00 on Friday. The firm has a market cap of $289.48 million and a PE ratio of -7.80. Verrica Pharmaceuticals Inc has a 52-week low of $6.44 and a 52-week high of $19.10. The firm has a 50-day moving average price of $9.52.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). On average, research analysts predict that Verrica Pharmaceuticals Inc will post -1.36 earnings per share for the current fiscal year.

A number of analysts recently issued reports on VRCA shares. HC Wainwright upped their target price on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Zacks Investment Research cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Kornitzer Capital Management Inc. KS boosted its position in shares of Verrica Pharmaceuticals by 36.6% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 447,341 shares of the company’s stock valued at $4,836,000 after purchasing an additional 119,921 shares during the period. BlackRock Inc. boosted its position in shares of Verrica Pharmaceuticals by 4.9% in the 4th quarter. BlackRock Inc. now owns 267,665 shares of the company’s stock valued at $2,182,000 after purchasing an additional 12,537 shares during the period. Diag Capital Management LP acquired a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at about $937,000. Asymmetry Capital Management L.P. raised its stake in Verrica Pharmaceuticals by 12.0% during the 1st quarter. Asymmetry Capital Management L.P. now owns 70,458 shares of the company’s stock valued at $762,000 after acquiring an additional 7,576 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Verrica Pharmaceuticals by 7.5% during the 4th quarter. Northern Trust Corp now owns 67,028 shares of the company’s stock valued at $546,000 after acquiring an additional 4,689 shares during the last quarter. 34.31% of the stock is owned by hedge funds and other institutional investors.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

See Also: Balance Sheet

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.